Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00426829 · ClinicalTrials.gov registry record · Phase 1
Proton Therapy and Bevacizumab for Primary Liver Tumors
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00426829: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00426829 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00426829, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Primary Objectives: 1. To evaluate the safety of the treatment of patients with technically or medically inoperable hepatocellular carcinoma and cholangiocarcinoma with proton therapy and concurrent bevacizumab biotherapy. 2. To identify the maximum tolerated dose (MTD) using this combination. Secondary Objectives: 1. To evaluate local control rate within the radiation field, hepatic control rate outside the treatment field, time to radiographic progression and 2 year survival rate. 2. To analyze dose-volume characteristics that influence the development of radiation induced liver disease (RILD) and GI bleeds that may occur. 3. To assess quality of life during and after chemoradiation therapy.
Interventions
- DRUG Bevacizumab
- RADIATION Proton Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2007-05 |
| Est. Completion | 2009-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00426829
The ClinicalTrials.gov registry entry for NCT00426829 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT00426829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00426829 about?
NCT00426829 is a clinical study titled "Proton Therapy and Bevacizumab for Primary Liver Tumors". Primary Objectives: 1. To evaluate the safety of the treatment of patients with technically or medically inoperable hepatocellular carcinoma and cholangiocarcinoma with proton therapy and concurrent bevacizumab biotherapy. 2. To identify the maximum tolerated dose (MTD) using this combination. Sec...
What is the current status of trial NCT00426829?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2007-05. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00426829?
The interventions under investigation include: Bevacizumab (DRUG), Proton Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT00426829?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.